Krogulski Kenneth 4

What Happened
Kenneth Krogulski, a director of Cumberland Pharmaceuticals, received equity awards on March 18, 2026. The filing shows two award transactions: 1,800 shares at $2.80 each ($5,040) and 4,000 shares at $2.80 each ($11,200), for a combined 5,800 shares valued at $16,240. These are awards/grants (transaction code A), not open-market purchases or sales — typically part of compensation or director equity plans rather than directional trades.

Key Details

• Transaction date: 2026-03-18; Filing date: 2026-03-20 (filed timely).
• Grants reported: 1,800 shares @ $2.80 = $5,040; 4,000 shares @ $2.80 = $11,200; total 5,800 shares = $16,240.
• Transaction code: A (award/grant).
• Shares owned after the transaction: not provided in the excerpt.
• No footnotes, 10b5-1 plan, tax-withholding or late-filing flags shown in the provided filing details.

Context
Equity awards to directors are commonly part of compensation (retainer or stock-award programs) and do not necessarily reflect a personal market view. For retail investors, awards increase insider ownership but should be interpreted alongside other insider activity and company fundamentals.